A Clinical Study of FT1 in Patients With Short Bowel Syndrome

A Randomized, Double-blind, Crossover, Placebo-controlled Phase IIa Clinical Study Evaluating the Efficacy and Safety of Recombinant Acylated Glucagon Like Peptide-2 Analog (FT1) for Injection in Patients With Short Bowel Syndrome

The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.

Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS.

Participants will

• Receive multiple injections of FT1 or placebo according to weight.
• Visit the clinic for assessment.

Study Overview

• Status: Recruiting
• Conditions: Short Bowel Syndrome; SBS
• Intervention / Treatment: Drug: FT1; Drug: Placebo

Detailed Description

In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, 8 adult SBS patients are treated with once-weekly FT1 or placebo (1:1) for 5 weeks, followed by a washout period of at least 6 weeks, and then the alternate treatment for a further 5 weeks.

Efficacy is evaluated through a 72 hour metabolic balance study conducted at baseline and at the end of each treatment cycle.

• Study Type: Interventional
• Enrollment (Estimated): 8
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Jing Sun; Phone Number: +86-13983367811; Email: sunj@pegbiocq.com

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 210002
      • Recruiting
      • General Hospital of Eastern Theater Command
      • Principal Investigator: Xinying Wang
      • Contact: Xinying Wang; Phone Number: 86-13983367811; Email: sunj@pegbiocq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 18 years, male or female.
• SBS secondary to surgical resection of the small intestine, screened for at least 12 months after pre intestinal resection surgery;
• Stable weight before screening; For patients requiring parenteral support (PS), PS volume remained stable (with changes in volume or energy content<25%) within 14 days prior to randomization;
• Willing to undergo colonoscopy and remove polyps assessed by researchers to be at risk of cancer;
• During the trial period, there were no plans to perform any major abdominal surgeries (such as intestinal resection exceeding 10% or surgeries that alter intestinal anatomy, such as stoma surgery);
• During the baseline metabolic balance study, the average daily fecal wet rearrangement amount was ≥ 800g;

Exclusion Criteria:

• Having undergone major abdominal surgery (such as intestinal resection exceeding 10%) within the past 6 months prior to screening;
• History of clinically significant intestinal adhesions and/or chronic abdominal pain;
• History of persistent radiation enteritis, celiac disease, refractory diarrhea, etc;
• Patients with malignant tumors within the past 5 years (excluding fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, local prostate cancer after radical surgery, and ductal carcinoma in situ of the breast after radical surgery);
• History of gallstones in the past 3 years, except for those who have undergone cholecystectomy for gallstones; Acute cholecystitis or biliary obstruction related diseases that have not been treated within the previous month or during the screening period;
• IBD patients with active inflammatory bowel disease (IBD), or requiring increased or altered immunosuppressive therapy in the past 3 months, or receiving biologic therapy in the past 6 months;
• Occurrence of central venous catheter-related bloodstream infections within 2 months prior to and during the screening period;
• Patients diagnosed with decompensated heart failure (NYHA grade III or above) and/or unstable angina and/or myocardial infarction from 6 months prior to screening until the first administration of the study drug;
• Screening for individuals with rectal bleeding within the first 3 months;
• Individuals with absorption instability caused by cystic fibrosis, untreated megacolon disease, or known DNA abnormalities (such as familial adenomatous polyposis, Fanconi syndrome);
• Serious active, uncontrolled, untreated, acute onset systemic diseases (such as cardiovascular, respiratory, renal, infectious, endocrine, liver or central nervous system, etc.);
• Pregnant or breastfeeding women.
• The investigator believes the subject is unsuitable for participating in this clinical study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FT1; FT1 will be administered subcutaneously once a week for 5 weeks during each treatment cycle.	Drug: FT1; FT1 treatment, once weekly for 5 weeks
Placebo Comparator: FT1 Placebo; FT1 Placebo will be administered subcutaneously once a week for 5 weeks during each treatment cycle.	Drug: Placebo; Placebo, once weekly for 5 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-related Adverse Events	To evaluate the adverse events as characterized by type, frequency, severity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 6.0, timing, seriousness, and relationship to study therapy after administration.	From the first administration to study completion, appropriately 5 months.
Changes in fecal wet weight from baseline to the end of treatment	The difference in changes in fecal wet weight in the 72-hour metabolic balance study after treatment compared to baseline	At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in urine volume from baseline to the end of treatment	The difference in changes in urine volume in the 72-hour metabolic balance study after treatment compared to baseline	At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
The Area Under the Curve from dosing to the time of the last measured concentration (AUC0-t)	Pharmacokinetic parameter	Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
Maximum plasma concentration (Cmax)	Pharmacokinetic parameter	Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
Changes in L-citrulline levels in plasma	Pharmacodynamic parameter	From Day 1 of the first cycle to the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)

Collaborators and Investigators

• Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): August 30, 2026
• Primary Completion (Estimated): April 15, 2027
• Study Completion (Estimated): April 15, 2027

Study Registration Dates

• First Submitted: July 3, 2026
• First Submitted That Met QC Criteria: July 9, 2026
• First Posted (Actual): July 15, 2026

Study Record Updates

• Last Update Posted (Actual): July 15, 2026
• Last Update Submitted That Met QC Criteria: July 9, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: short bowel syndrome; SBS; GLP-2; FT1
• Additional Relevant MeSH Terms: Postoperative Complications; Pathologic Processes; Intestinal Diseases; Digestive System Diseases; Gastrointestinal Diseases; Malabsorption Syndromes; Pathological Conditions, Signs and Symptoms; Short Bowel Syndrome
• Other Study ID Numbers: FT1-A201

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No